Covaxin Phase 3 trial result shows 77.8% efficacy against symptomatic Covid

Covaxin Phase 3 trial result shows 77.8% efficacy against symptomatic Covid

The Subject Expert Committee (SEC) under India's drug regulator on Tuesday approved Bharat Biotech' phase-3 trial efficacy data for its Covid-19 vaccine 'Covaxin.' According to the data submitted, Covaxin has shown the efficacy of 77.8% from the trial conducted on 25,800 subjects.

The Hyderabad-based COVID vaccine manufacturing company Bharat Biotech submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend..

The phase III data of its vaccine have been questioned various times and that is what makes the data crucial which will ascertain the efficacy of the vaccine.

The World Health Organisation (WHO) has extended its emergency use nod to a total of seven manufacturers worldwide. Of these, three are for those producing the Oxford-AstraZeneca vaccine, including one by the Serum Institute of India after Covishield was cleared by the Drug Controller General of India (DCGI). The other vaccine makers are Pfizer-BioNtech, Moderna, Janssen (which is making the single-shot Johnson & Johnson vaccine),

and the Chinese Sinopharm.